7 December 2022 - Expedited drug approvals slowed this year as the FDA’s controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders.

With less than a month remaining in the year, the FDA’s drug centre has granted 10 accelerated approvals — fewer than the tally in each of the last five years, when use of the program reached all-time highs.

Read Associated Press article